-
1
-
-
0034670036
-
The molecular biology of chronic myeloid leukemia
-
Deininger, M. W., Goldman, J. M., and Melo, J. V. The molecular biology of chronic myeloid leukemia. Blood, 96: 3343-3356, 2000.
-
(2000)
Blood
, vol.96
, pp. 3343-3356
-
-
Deininger, M.W.1
Goldman, J.M.2
Melo, J.V.3
-
2
-
-
0036139993
-
STI571: A paradigm of new agents for cancer therapeutics
-
Mauro, M. J., O'Dwyer, M., Heinrich, M. C., and Druker, B. J. STI571: a paradigm of new agents for cancer therapeutics. J. Clin. Oncol., 20: 325-334, 2002.
-
(2002)
J. Clin. Oncol.
, vol.20
, pp. 325-334
-
-
Mauro, M.J.1
O'Dwyer, M.2
Heinrich, M.C.3
Druker, B.J.4
-
3
-
-
0035810142
-
Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
-
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Fernandes Reese, S., Ford, J. M., Capdeville, R., and Talpaz, M. Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med., 344: 1038-1042, 2001.
-
(2001)
N. Engl. J. Med.
, vol.344
, pp. 1038-1042
-
-
Druker, B.J.1
Sawyers, C.L.2
Kantarjian, H.3
Resta, D.J.4
Fernandes Reese, S.5
Ford, J.M.6
Capdeville, R.7
Talpaz, M.8
-
4
-
-
0037093092
-
Imatinib induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: Results of a phase II study
-
Sawyers, C. L., Hochhaus, A., Feldman, E., Goldman, J. M., Miller, C. B., Ottmann, O. G., Schiffer, C. A., Talpaz, M., Guilhot, F., Deininger, M. W. N., Fischer, T., O'Brien, S. G., Stone, R. M., Gambacorti-Passerini, C. B., Russell, N. H., Reiffers, J. J., Shea, T. C., Chapuis, B., Coutre, S., Tura, S., Morra, E., Larson, R. A., Saven, A., Peschel, C., Gratwohl, A., Mandelli, F., Ben-Am, M., Gathmann, I., Capdeville, R., Paquette, R. L., and Druker, B. J. Imatinib induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a phase II study. Blood, 99: 3530-3539, 2002.
-
(2002)
Blood
, vol.99
, pp. 3530-3539
-
-
Sawyers, C.L.1
Hochhaus, A.2
Feldman, E.3
Goldman, J.M.4
Miller, C.B.5
Ottmann, O.G.6
Schiffer, C.A.7
Talpaz, M.8
Guilhot, F.9
Deininger, M.W.N.10
Fischer, T.11
O'Brien, S.G.12
Stone, R.M.13
Gambacorti-Passerini, C.B.14
Russell, N.H.15
Reiffers, J.J.16
Shea, T.C.17
Chapuis, B.18
Coutre, S.19
Tura, S.20
Morra, E.21
Larson, R.A.22
Saven, A.23
Peschel, C.24
Gratwohl, A.25
Mandelli, F.26
Ben-Am, M.27
Gathmann, I.28
Capdeville, R.29
Paquette, R.L.30
Druker, B.J.31
more..
-
5
-
-
0035282735
-
Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336
-
Reichert, A., Heisterkamp, N., Daley, G. Q., and Groffen, J. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. Blood, 97: 1399-1403, 2001.
-
(2001)
Blood
, vol.97
, pp. 1399-1403
-
-
Reichert, A.1
Heisterkamp, N.2
Daley, G.Q.3
Groffen, J.4
-
6
-
-
0035282901
-
Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia
-
Peters, D. G., Hoover, R. R., Gerlach, M. J., Koh, E. Y., Zhang, H., Choe, K., Kirschmeier, P., Bishop, W. R., and Daley, G. Q. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood, 97: 1404-1412, 2001.
-
(2001)
Blood
, vol.97
, pp. 1404-1412
-
-
Peters, D.G.1
Hoover, R.R.2
Gerlach, M.J.3
Koh, E.Y.4
Zhang, H.5
Choe, K.6
Kirschmeier, P.7
Bishop, W.R.8
Daley, G.Q.9
-
7
-
-
0035383789
-
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial
-
Karp, J. E., Lancet, J. E., Kaufmann, S. H., End, D. W., Wright, J. J., Bol, K., Horak, I., Tidwell, M. L., Liesveld, J., Kottke, T. J., Ange, D., Buddharaju, L., Gojo, I., Highsmith, W. E., Belly, R. T., Hohl, R. J., Rybak, M. E., Thibault, A., and Rosenblatt, J. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood, 97: 3361-3369, 2001.
-
(2001)
Blood
, vol.97
, pp. 3361-3369
-
-
Karp, J.E.1
Lancet, J.E.2
Kaufmann, S.H.3
End, D.W.4
Wright, J.J.5
Bol, K.6
Horak, I.7
Tidwell, M.L.8
Liesveld, J.9
Kottke, T.J.10
Ange, D.11
Buddharaju, L.12
Gojo, I.13
Highsmith, W.E.14
Belly, R.T.15
Hohl, R.J.16
Rybak, M.E.17
Thibault, A.18
Rosenblatt, J.19
-
8
-
-
0037372488
-
Efficacy of the farnesyl transferase inhibitor, ZARNES-TRATM (R115777), in chronic myeloid leukemia and other other hematological malignancies
-
Cortes, J. E., Albitar, M., Thomas, D., Giles, F., Kurzrock, R., Thibault, A., Rackoff, W., Koller, C., O'Brien, S., Garcia-Manero, G., Talpaz, M., and Kantarjian, H. Efficacy of the farnesyl transferase inhibitor, ZARNES-TRATM (R115777), in chronic myeloid leukemia and other other hematological malignancies. Blood, 101: 1692-1697, 2003.
-
(2003)
Blood
, vol.101
, pp. 1692-1697
-
-
Cortes, J.E.1
Albitar, M.2
Thomas, D.3
Giles, F.4
Kurzrock, R.5
Thibault, A.6
Rackoff, W.7
Koller, C.8
O'Brien, S.9
Garcia-Manero, G.10
Talpaz, M.11
Kantarjian, H.12
-
9
-
-
0344611212
-
Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjuction with imatinib against Bcr-Abl-positive cells
-
Nakajima, A., Tauchi, T., Sumi, M., Bishop, W. R., and Ohyashiki, K. Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjuction with imatinib against Bcr-Abl-positive cells. Mol. Cancer Ther., 2: 219-224, 2003.
-
(2003)
Mol. Cancer Ther.
, vol.2
, pp. 219-224
-
-
Nakajima, A.1
Tauchi, T.2
Sumi, M.3
Bishop, W.R.4
Ohyashiki, K.5
-
10
-
-
0036683409
-
Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336
-
Hoover, R. R., Mahon, F. X., Melo, J. V., and Daley, G. Q. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood, 100: 1068-1071, 2002.
-
(2002)
Blood
, vol.100
, pp. 1068-1071
-
-
Hoover, R.R.1
Mahon, F.X.2
Melo, J.V.3
Daley, G.Q.4
-
11
-
-
0036850514
-
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
-
Baltimore
-
Hochhaus, A., Kreil, S., Corbin, A. S., La Rosée, P., Müller, M. C., Lahaye, T., Hanfstein, B., Schoch, C., Cross, N. C. P., Berger, U., Gschaidmeier, H., Druker, B. J., and Hehlmann, R. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia (Baltimore), 16: 2190-2196, 2002.
-
(2002)
Leukemia
, vol.16
, pp. 2190-2196
-
-
Hochhaus, A.1
Kreil, S.2
Corbin, A.S.3
La Rosée, P.4
Müller, M.C.5
Lahaye, T.6
Hanfstein, B.7
Schoch, C.8
Cross, N.C.P.9
Berger, U.10
Gschaidmeier, H.11
Druker, B.J.12
Hehlmann, R.13
-
12
-
-
0001686739
-
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
-
Cold Spring Harbor
-
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., and Sawyers, C. L. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cells (Cold Spring Harbor), 2: 117-125, 2002.
-
(2002)
Cancer Cells
, vol.2
, pp. 117-125
-
-
Shah, N.P.1
Nicoll, J.M.2
Nagar, B.3
Gorre, M.E.4
Paquette, R.L.5
Kuriyan, J.6
Sawyers, C.L.7
-
13
-
-
0037199996
-
Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571
-
Corbin, A. S., Buchdunger, E., Pascal, F., and Druker, B. J. Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J. Biol. Chem., 277: 32214-32219, 2002.
-
(2002)
J. Biol. Chem.
, vol.277
, pp. 32214-32219
-
-
Corbin, A.S.1
Buchdunger, E.2
Pascal, F.3
Druker, B.J.4
-
14
-
-
0038375012
-
Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib
-
in press
-
Corbin, A. S., La Rosée, P., Stoffregen, E., Druker, B. J., and Deininger, M. W. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood, in press, 2003.
-
(2003)
Blood
-
-
Corbin, A.S.1
La Rosée, P.2
Stoffregen, E.3
Druker, B.J.4
Deininger, M.W.5
-
15
-
-
0038584950
-
Imatinib (STI571, Gleevec) as initial therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia (CML): Results of a randomized Phase III study vs interferon-α + cytarabine
-
for the IRIS (International Randomized IFN vs STI571) Study Group
-
Larson, R. A. for the IRIS (International Randomized IFN vs STI571) Study Group. Imatinib (STI571, Gleevec) as initial therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia (CML): results of a randomized Phase III study vs interferon-α + cytarabine. Blood, 100: 4a, 2002.
-
(2002)
Blood
, vol.100
-
-
Larson, R.A.1
-
16
-
-
0037568145
-
Molecular responses to imatinib (STI571) or interferon + Ara-C as initial therapy for CML: Results in the IRIS study
-
Hughes, T., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Capdeville, R., Gathmann, I., Bolton, A. E., Goldman, J. M., and Radich, J. Molecular responses to imatinib (STI571) or interferon + Ara-C as initial therapy for CML: results in the IRIS study. Blood, 100: 93a, 2002.
-
(2002)
Blood
, vol.100
-
-
Hughes, T.1
Kaeda, J.2
Branford, S.3
Rudzki, Z.4
Hochhaus, A.5
Capdeville, R.6
Gathmann, I.7
Bolton, A.E.8
Goldman, J.M.9
Radich, J.10
-
17
-
-
0036090222
-
Primitive, quiescent. Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
-
Graham, S. M., Jorgensen, H. G., Allan, E., Pearson, C., Alcorn, M. J., Richmond, L., and Holyoake, T. L. Primitive, quiescent. Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood, 99: 319-325, 2002.
-
(2002)
Blood
, vol.99
, pp. 319-325
-
-
Graham, S.M.1
Jorgensen, H.G.2
Allan, E.3
Pearson, C.4
Alcorn, M.J.5
Richmond, L.6
Holyoake, T.L.7
-
18
-
-
0032981812
-
Targeting farnesyltransferase: Is Ras relevant?
-
Prendergast, G. C., and Du, W. Targeting farnesyltransferase: is Ras relevant? Drug Resist. Update, 2: 81-84, 1999.
-
(1999)
Drug Resist. Update
, vol.2
, pp. 81-84
-
-
Prendergast, G.C.1
Du, W.2
-
19
-
-
0033016719
-
Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB
-
Du, W., Lebowitz, P. F., and Prendergast, G. C. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol. Cell. Biol., 19: 1831-1840, 1999.
-
(1999)
Mol. Cell. Biol.
, vol.19
, pp. 1831-1840
-
-
Du, W.1
Lebowitz, P.F.2
Prendergast, G.C.3
|